Q-omics provides the consensus-scored SNORA58B profile across patient tissues and cancer cell-line models. SNORA58B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORA58B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SNORA58B RNA expression shows 9,526 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where SNORA58B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA58B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA58B survival associations across molecular data types. SNORA58B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA58B RNA expression–survival associations across cancer types. High SNORA58B expression shows unfavorable associations in ACC, KIRC, THCA, KIRP, STAD and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORA58B RNA expression.
This table summarizes SNORA58B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA58B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA58B shows higher tumor expression in KIRC, COAD, BRCA, LUSC, ESCA and CHOL. The KIRC box plot shows higher SNORA58B RNA expression in tumor versus normal tissue (log2 FC = +0.267, t-test p < 0.001).
This table shows molecular features associated with SNORA58B in patient tissues and cancer cell lines. In patient samples, SNORA58B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
